Loading...
Market
What will the market share of GLP-1 drugs in diabetes treatment be by the end of 2024?
2
Resolution / Starting Odds
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Market analysis reports from reputable firms like IMS Health or IQVIA
Story
Study Finds Ozempic, Wegovy Lower Cancer Risk in Type 2 Diabetes Patients by 10 out of 13
Jul 5, 2024, 05:09 PM
A new study has found that GLP-1 drugs, including Ozempic and Wegovy, significantly reduce the risk of cancer in patients with type 2 diabetes. The retrospective cohort study, which analyzed electronic health records of approximately 1.65 million people over 15 years, revealed that patients on GLP-1 medications had a lower risk for 10 out of 13 obesity-related cancers compared to those on insulin therapy. The findings, published Friday in JAMA Network Open, were based on data from 113 million US patients and suggest a promising alternative for reducing cancer risk in diabetic patients.
View original story
Similar markets
Below 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
Above 40% • 25%
Less than 20% • 33%
20% - 50% • 33%
More than 50% • 34%
Wegovy • 25%
Zepbound • 25%
Ozempic • 25%
Other • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
0-10% • 25%
11-25% • 25%
26-50% • 25%
More than 50% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Increase by less than 5% • 33%
Increase by 5% to 10% • 34%
Increase by more than 10% • 33%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Pfizer • 25%
Other • 25%
Less than 30% • 25%
30% to 40% • 25%
40% to 50% • 25%
More than 50% • 25%